 |
|
|
| |
Low Level of Virologic Failure and Resistance in ART-Experienced, Integrase
Inhibitor-Naive Participants Receiving Dolutegravir (DTG) and Nucleoside Reverse
Transcriptase Inhibitors (NRTIs) Combined Regimens: 10-Year Follow-up in the
SAILING Study
|
| |
| |
AIDS 2022 Juy 29-Aug 1 Montreal
Ruolan Wang,1 Joe Horton,2 Aditya Joshi,3 Netsanet Gebremedhin,2 Brian Wynne,1 Sandy Griffith,1 Mark Underwood1
1ViiV Healthcare, Durham, NC, USA; 2PAREXEL International, Durham, NC, USA; 3GSK, Bangalore, Ind
|
| |
|
|
|
|
|
